Deucrictibant Pill Cuts Angioedema Attacks 83 Percent

Pharvaris's deucrictibant XR tablet cut monthly hereditary angioedema attacks by 83 percent against placebo in the Phase 3 CHAPTER-3 trial, the company said on November 12, 2026. Marc A. Riedl presented the full results on November 14 at the ACAAI annual meeting in Phoenix. The drug is investigational and isn't approved anywhere.

Hereditary angioedema is an inherited condition that causes sudden, sometimes dangerous swelling. Deucrictibant blocks the bradykinin B2 receptor, a switch in the pathway that drives those attacks. Most preventive options today involve injections, so a once-daily pill would change the daily routine of staying ahead of the disease.

CHAPTER-3, registered as NCT06669754, randomized 85 participants from 21 countries in a 2-to-1 split: 55 people took deucrictibant XR 40 milligrams once a day and 30 took a placebo, for 24 weeks. The trial enrolled adults and adolescents 12 and older, including people whose angioedema comes with normal C1 inhibitor levels.

The 83 percent reduction in the mean monthly attack rate covered all angioedema types and cleared statistical significance at p<0.0001. A post hoc look at the 80 participants with type 1 or type 2 disease showed an 87 percent reduction. Pharvaris says the trial met its primary endpoint and every secondary endpoint.

The safety table is the part a careful reader shouldn't skip. Treatment-emergent adverse events hit 76.4 percent of treated patients against 56.7 percent on placebo, with upper respiratory infection, nasopharyngitis and headache most common in both groups. All but four treated patients stayed at Grade 1 or 2 severity.

The Grade 3 events were one tooth infection and two liver enzyme elevations. One of the two liver patients stopped the drug, and the other finished the study. The company reports no treatment-related serious adverse events and no treatment-related cardiovascular events, and it recorded no clinically significant changes in heart rate, blood pressure or ECG readings.

The sample is small, and that's the honest limit on the result. Eighty-five participants can establish that a drug prevents attacks, but rare harms don't always surface at that size, and two liver signals in 55 treated patients is a rate regulators will weigh against the benefit. The trial also ran 24 weeks, so it says less about years of daily use.

Pharvaris is preparing the approval dossier for the XR tablet with a submission planned for the first half of 2027. A separate immediate-release version, aimed at treating attacks as they happen, is already under FDA review with a decision date of April 23, 2027. The company held 283 million euros in cash on September 30, 2026, which funds the wait.